209 related articles for article (PubMed ID: 33968764)
1. Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies.
Wenzel M; Preisser F; Hoeh B; Schroeder M; Würnschimmel C; Steuber T; Heinzer H; Banek S; Ahrens M; Becker A; Karakiewicz PI; Chun FKH; Kluth LA; Mandel P
Front Oncol; 2021; 11():659135. PubMed ID: 33968764
[TBL] [Abstract][Full Text] [Related]
2. Whole blood
Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA
Transl Androl Urol; 2021 Apr; 10(4):1688-1699. PubMed ID: 33968657
[TBL] [Abstract][Full Text] [Related]
3. Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer.
Mitsui Y; Yamabe F; Hori S; Uetani M; Aoki H; Sakurabayashi K; Okawa M; Kobayashi H; Nagao K; Nakajima K
Front Oncol; 2023; 13():1162820. PubMed ID: 37333829
[TBL] [Abstract][Full Text] [Related]
4. Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patients.
Wenzel M; Hoeh B; Hurst F; Koll F; Cano Garcia C; Humke C; Steuber T; Tilki D; Traumann M; Banek S; Chun FKH; Mandel P
Prostate; 2024 May; ():. PubMed ID: 38812332
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2019 Mar; 39(3):1391-1396. PubMed ID: 30842173
[TBL] [Abstract][Full Text] [Related]
6. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
7. Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting?
Dülgar Ö; Özyükseler DT; Başak M; Ay S; Tural D; Yıldırım ME; Gümüş M
J Oncol Pharm Pract; 2021 Sep; 27(6):1388-1394. PubMed ID: 32847482
[TBL] [Abstract][Full Text] [Related]
8. Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.
Vermunt MAC; van Nuland M; van der Heijden LT; Rosing H; Beijnen JH; Bergman AM
Cancer Chemother Pharmacol; 2022 Jun; 89(6):785-793. PubMed ID: 35467095
[TBL] [Abstract][Full Text] [Related]
9. A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer.
Lee CS; Lam SY; Liu A; Sison C; Zhu XH
Clin Med Insights Oncol; 2023; 17():11795549231152073. PubMed ID: 36744171
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
Schweizer MT; Gulati R; Mostaghel EA; Nelson PS; Montgomery RB; Yu EY; Cheng HH
Med Oncol; 2016 Jul; 33(7):77. PubMed ID: 27300548
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ
Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
[TBL] [Abstract][Full Text] [Related]
12. Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.
Yadav S; Hart SN; Hu C; Hillman D; Lee KY; Gnanaolivu R; Na J; Polley EC; Couch FJ; Kohli M
JCO Precis Oncol; 2019; 3():. PubMed ID: 32923857
[TBL] [Abstract][Full Text] [Related]
13. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
[TBL] [Abstract][Full Text] [Related]
14. Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.
Hahn AW; Stenehjem DD; Alex AB; Gill DM; Cheng HH; Kessler ER; Chittoria N; Twardowski P; Vaishampayan U; Agarwal N
Urol Oncol; 2019 Jun; 37(6):352.e19-352.e24. PubMed ID: 30770300
[TBL] [Abstract][Full Text] [Related]
15. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S
Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810
[TBL] [Abstract][Full Text] [Related]
16. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
17. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.
Francini E; Gray KP; Shaw GK; Evan CP; Hamid AA; Perry CE; Kantoff PW; Taplin ME; Sweeney CJ
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):420-427. PubMed ID: 30643173
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Time to Castration Resistance on Overall Survival and Success of Docetaxel Treatment in Castration Resistant Prostate Cancer Patients.
Suer E; Hamidi N; Akpinar C; Gokce MI; Gulpinar O; Turkolmez K; Beduk Y; Baltaci S
Urol J; 2019 Oct; 16(5):453-457. PubMed ID: 30636274
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis.
Valeriani M; Detti B; Fodor A; Caini S; Borghesi S; Trippa F; Triggiani L; Bruni A; Russo D; Saldi S; Di Staso M; Francolini G; Lancia A; Marinelli L; Di Muzio N; Aristei C; Livi L; Magrini SM; Ingrosso G
Radiol Med; 2022 Jan; 127(1):108-116. PubMed ID: 34748151
[TBL] [Abstract][Full Text] [Related]
20. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
